Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
IGF2-AS Biologics Sequence Review Report 2026: Putative insulin-like growth factor 2 antisense gene protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of IGF2-AS sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HGS Biologics Sequence Review Report 2026: Hepatocyte growth factor-regulated tyrosine kinase substrate Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HGS sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HEPACAM Biologics Sequence Review Report 2026: Hepatic and glial cell adhesion molecule Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HEPACAM sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HDGFL3 Biologics Sequence Review Report 2026: Hepatoma-derived growth factor-related protein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HDGFL3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HDGFL2 Biologics Sequence Review Report 2026: Hepatoma-derived growth factor-related protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HDGFL2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HDGFL1 Biologics Sequence Review Report 2026: Hepatoma-derived growth factor-like protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HDGFL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HCAR2 Biologics Sequence Review Report 2026: Hydroxycarboxylic acid receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HCAR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HCAR1 Biologics Sequence Review Report 2026: Hydroxycarboxylic acid receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HCAR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HBEGF Biologics Sequence Review Report 2026: Proheparin-binding EGF-like growth factor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of HBEGF sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GRK2 Biologics Sequence Review Report 2026: G protein-coupled receptor kinase 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GRK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GRIN1 Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GRIN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GNRHR2 Biologics Sequence Review Report 2026: Putative gonadotropin-releasing hormone II receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of GNRHR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.